{"disease":{"id":"thymic-carcinoma","name":"Thymic carcinoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":3},"drugs":{"marketed":[{"drug_id":"lenvatinib","indication_name":"Thymic carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lenvima","generic_name":"LENVATINIB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":"1053.0","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT06301945","title":"Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":1020,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT05667948","title":"Molecular Analysis and Treatment Options of Thymic Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT03170804","title":"Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Aventura Hospital and Medical Center","has_results":false},{"nct_id":"NCT06402708","title":"Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07179341","title":"Survival Nomogram for Patients With Thymic Carcinoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Weijie Ye","has_results":false},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT05544929","title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04234113","title":"Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":115,"lead_sponsor_name":"SOTIO Biotech AG","has_results":true},{"nct_id":"NCT06121271","title":"Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":110,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT06692062","title":"Hypofractionated Radiotherapy for Thymic Epithelial Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Rongrong Zhou","has_results":false},{"nct_id":"NCT04469725","title":"KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":95,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT07181720","title":"CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT03583086","title":"Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"Vanderbilt-Ingram Cancer Center","has_results":true},{"nct_id":"NCT05461430","title":"Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Travera Inc","has_results":false},{"nct_id":"NCT01011439","title":"Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":72,"lead_sponsor_name":"Tiziana Life Sciences LTD","has_results":true},{"nct_id":"NCT04662645","title":"Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancies and Their Caregivers","phase":"NA","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03921671","title":"Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Claudia Proto","has_results":false},{"nct_id":"NCT03449173","title":"Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":56,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT03076554","title":"A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":56,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06186726","title":"Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Jian Chen","has_results":false},{"nct_id":"NCT04710628","title":"Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"MedSIR","has_results":false},{"nct_id":"NCT04554524","title":"Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT03295227","title":"Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05832827","title":"First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"National Cancer Center, Japan","has_results":false},{"nct_id":"NCT07479628","title":"Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":31,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT01100944","title":"A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":26,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06019468","title":"Neoadjuvant Treatment For Locally Advanced Thymic Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT06141369","title":"Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)","phase":"NA","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT03694002","title":"Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT04430842","title":"Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Quadriga Biosciences, Inc.","has_results":false},{"nct_id":"NCT01143545","title":"Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03463460","title":"Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Dwight Owen","has_results":false},{"nct_id":"NCT02062632","title":"Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT04925947","title":"A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":true}],"total":35},"guidelines":[],"source":"Drug Landscape verified database"}